We have tested the hypothesis that IgM antibodies produced against proteins up-regulated or modified in response to tumor formation would be present and more readily detected than their respective antigens; and, as such, would represent useful biomarkers as indicators of early stage lung cancer. This evidence concerns the gene CD40LG and lung carcinoma.